Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Nucl Med Commun ; 24(3): 321-6, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12612474

ABSTRACT

Tc-tetrofosmin seems to show a prolonged thyroid retention when compared with Tc-sestamibi; this may explain its poorer performance in the dual-phase parathyroid scintigraphy. In order to verify objectively whether and to what extent Tc-sestamibi and Tc-tetrofosmin uptake and retention differ in the thyroid gland, we performed a head-to-head comparison between the tracers in 86 euthyroid subjects enrolled in five centres. Data were compared with those of Tc-pertechnetate obtained from the same subjects. For comparison purposes, quantitative data from the salivary glands were also obtained. Tc-sestamibi showed a higher early thyroid uptake (2.26+/-0.52 vs. 2.01+/-0.49, respectively; P<0.002) and a lower retention (1.4+/-0.37 vs. 1.65+/-0.58, respectively; P<0.002) when compared with Tc-tetrofosmin. This finding provides an objective basis for the poorer results of Tc-tetrofosmin in dual-phase parathyroid scintigraphy. Delayed Tc-tetrofosmin salivary gland uptake was unexpectedly high and approached the Tc-pertechnetate value (2.29+/-0.56 vs. 2.46+/-0.75, respectively; P =not significant). This finding should be kept in mind in order to avoid interpretation pitfalls in thyroid and parathyroid imaging with Tc-tetrofosmin, as well as in other oncological imaging of the neck region. This study definitely establishes that Tc-tetrofosmin and Tc-sestamibi are not twin but rather sibling tracers.


Subject(s)
Hyperparathyroidism/diagnostic imaging , Organophosphorus Compounds/pharmacokinetics , Organotechnetium Compounds/pharmacokinetics , Salivary Glands/diagnostic imaging , Sodium Pertechnetate Tc 99m/pharmacokinetics , Technetium Tc 99m Sestamibi/pharmacokinetics , Thyroid Gland/diagnostic imaging , Biological Transport , Humans , Italy , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Reproducibility of Results , Salivary Glands/metabolism , Thyroid Gland/metabolism , Tissue Distribution
3.
Minerva Chir ; 55(1-2): 77-87, 2000.
Article in Italian | MEDLINE | ID: mdl-10832290

ABSTRACT

A case of a young male operated on for acute appendicitis due to a carcinoid of the base is reported. Since the tumor was infiltrating the resection margin of the appendix, the patient was later treated with a right hemicolectomy. Carcinoid tumor is unusual, but can be encountered several times during the career of a surgeon (1/200-300 appendicectomy). The tumor is more frequent in women (2-4:1), located at the tip of the appendix (62-78%) and has a diameter less than 1 cm in 70-95% of cases. It is more frequently diagnosed incidentally after an operation for acute appendicitis and occasionally during other procedures (colectomy, cholecystectomy, salpingectomy). Liver metastases are rare (< 2%), related to the dimension of the primitive tumor (21-100% when > 2 cm) and can cause a "carcinoid syndrome": flush, diarrhea bronchoconstriction, cardiac valve disease. Diagnosis is made by the pathologist and staging by conventional radiologic procedures (TAC, US), dosage of neuroendocrine mediators such as 24 hours urinary 5-HIAA. Nowadays 111In-octreotide scintigraphy (SRS) has an 86% sensitivity to detect the carcinoid and is useful for staging and for planning a surgical intervention. Simple appendectomy is adequate treatment for appendiceal carcinoids less than 1 cm in diameter. Adequate treatment for tumors greater than 2 cm is right hemicolectomy. A point of controversy is what to do for tumors in the 1 to 2 cm range. It seems that appendectomy alone is sufficient except in those cases when mesoappendiceal invasion is identified. When surgical margins after appendectomy are not free of tumor, additional surgery seems warranted. Carcinoid tumor of the appendix has a good prognosis with a 5-year-survival rate, of 85.9-100%. When liver metastases are encountered octreotide can relieve symptoms and sometimes the progression of the disease.


Subject(s)
Appendiceal Neoplasms/surgery , Carcinoid Tumor/surgery , Abdomen/diagnostic imaging , Adult , Age Factors , Appendectomy , Appendiceal Neoplasms/diagnosis , Appendiceal Neoplasms/pathology , Appendix/pathology , Carcinoid Tumor/diagnosis , Carcinoid Tumor/pathology , Female , Follow-Up Studies , Humans , Indium Radioisotopes , Male , Octreotide , Radionuclide Imaging , Radiopharmaceuticals , Sex Factors , Time Factors , Tomography, X-Ray Computed
4.
Eur J Nucl Med ; 26(8): 907-11, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10436206

ABSTRACT

The aim of the study was to quantitatively compare the scintigraphic images of the thyroid and abnormal parathyroid glands obtained with technetium-99m tetrofosmin and thallium-201 in patients with hyperparathyroidism. Forty-six patients with hyperparathyroidism underwent (201)Tl (74 MBq), (99m)Tc-pertechnetate (74 MBq) and (99m)Tc-tetrofosmin (555-740 MBq) scintigraphy in a single session. Image analysis included the computation of the thyroid/background ratio in the whole study population and the parathyroid/background ratio, parathyroid/thyroid ratio and diagnostic sensitivity in 17 patients who underwent parathyroid surgery. The pertechnetate subtraction technique was used. (201)Tl and (99m)Tc-tetrofosmin showed a similar thyroid/background ratio (1.79+/-0.41 and 1.81+/-0. 47, respectively, P=NS); however, (99m)Tc-tetrofosmin showed a higher parathyroid/background ratio than (201)Tl (2.06+/-0.54 vs 1. 79+/- 0.50, P=0.007). Despite the superior quality of (99m)Tc-tetrofosmin images, both tracers showed identical sensitivity in detecting enlarged parathyroid glands in patients with primary hyperparathyroidism (89%) and in those with secondary hyperparathyroidism (50%).


Subject(s)
Hyperparathyroidism, Secondary/diagnostic imaging , Hyperparathyroidism/diagnostic imaging , Organophosphorus Compounds , Organotechnetium Compounds , Thallium Radioisotopes , Thyroid Gland/diagnostic imaging , Adenoma/diagnostic imaging , Female , Humans , Male , Parathyroid Glands/diagnostic imaging , Parathyroid Neoplasms/diagnostic imaging , Radionuclide Imaging , Radiopharmaceuticals , Sensitivity and Specificity , Sodium Pertechnetate Tc 99m
5.
Nucl Med Commun ; 17(8): 706-10, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8878132

ABSTRACT

The aim of this study was to evaluate whether 99Tcm-tetrofosmin is a suitable agent for parathyroid scintigraphy. Ten patients with hyperparathyroidism and two normal subjects underwent parathyroid scintigraphy with both 99Tcm-tetrofosmin and 201TI. Thyroid image subtraction was performed with 99Tcm-pertechnetate. In the 10 patients with hyperparathyroidism, the scintigraphic results were compared with the surgical findings, which showed seven parathyroid adenomas, two parathyroid adenomas with a co-existing thyroid adenoma, and one thyroid carcinoma. Both 99Tcm-tetrofosmin and 201T1 revealed eight true-positive results, one false-negative results and one false-positive result, with concordance in 8 of 10 patients. The image quality with 99Tcm-tetrofosmin of both the raw and 99Tcm-pertechnetate subtracted images was always superior compared with that with 201T1. On the basis of the diagnostic results and the favourable dosimetric characteristics, we conclude that 99Tcm-tetrofosmin is a suitable agent for parathyroid scintigraphy.


Subject(s)
Organophosphorus Compounds , Organotechnetium Compounds , Parathyroid Glands/diagnostic imaging , Adenoma/diagnostic imaging , Adenoma/surgery , Adult , Aged , False Negative Reactions , False Positive Reactions , Female , Humans , Hyperparathyroidism/diagnostic imaging , Hyperparathyroidism/surgery , Male , Middle Aged , Parathyroid Neoplasms/diagnostic imaging , Parathyroid Neoplasms/surgery , Radionuclide Imaging , Sodium Pertechnetate Tc 99m , Thallium Radioisotopes , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...